ACAAI COVID-19 VACCINE COMPARISON CHART – 08/24/2022

Vaccine	Pfizer-BioNTech	Moderna	J& J Vaccine	Novavax
Mechanism of action	Vaccine contains 30 mcg of a nucleoside-modified messenger RNA (mod RNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2.	Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.	Replication-incompetent adenovirus type 26 (Ad26)- vector vaccine encoding a stabilized variant of the SARS-CoV-2 S protein.	Vaccine contains 5 mcg of SARS-CoV-2 recombinant spike (rS) protein and 50 mcg Matrix-M adjuvants. The rS protein is produced by recombinant DNA technology using a baculovirus expression system in an insect cell line.
Ages approved	6 mos. and up	6 mos. and up	18 and up	12 and up
Schedule	CDC At a Glance COVID-19 Vaccine Schedules	CDC At a Glance COVID-19 Vaccine Schedules	CDC At a Glance COVID-19 Vaccine Schedules	CDC At a Glance COVID-19 Vaccine Schedules
Overview and Safety	CDC: Pfizer Overview and Safety	CDC: Moderna Overview and Safety	CDC: J&J Overview and Safety	CDC: Novavax Overview and Safety
Storage	1.Vials must be kept frozen between -80ºC to -60ºC (-112ºF to -76ºF) and protected from light. 2.If an ultra-low temperature freezer is not available, the thermal container may be used as temporary storage 3. Thaw and then store undiluted vials in the refrigerator [2ºC to 8ºC	1.Vaccine multiple-dose vials are stored frozen between -25ºC to -15ºC (-13ºF to 5ºF protected from light. 2.Do not store on dry ice or below -40ºC (-40ºF). 3.Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use.	1.Stored at 2°C to 8°C (36°F to 46°F)] in a multi-dose vial containing 5 doses, protected from light. 2.Unpunctured vials may be stored between 9°C to 25°C (47°F to 77°F) for up to 12 hours. 2. After withdrawal of first dose, the vial should be held	1. Store between 2°C to 8°C (36° to 46°F). 2. 10 dose vial. 3. After the first needle puncture, hold the vial between 2°C to 25°C (36°F to 77°F) for up to 6 hours.

ACAAI COVID-19 VACCINE COMPARISON CHART – 08/24/2022

Vaccine	Pfizer-BioNTech	Moderna	J& J Vaccine	Novavax
	(35ºF to 46ºF)] for up to 5 days (120 hours) 4 For immediate use, thaw undiluted vials at room temperature [up to 25ºC (77ºF)] for 30 minutes. 5. Undiluted vials may be stored at room temperature for no more than 2 hours.	4.Unpunctured vials may be stored between 8° to 25°C (46° to 77°F) for up to 12 hours. 5. After the first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77°F). Discard vial after 6 hours. Do not refreeze	between 2° to 8°C (36° to 46°F) for up to 6 hours or at room temperature for up to 2 hours.	
VAERS	Mandatory Reporting of adverse events Including MIS, hospitalization/ fatal COVID	Mandatory Reporting of adverse events including MIS, hospitalization/ fatal COVID	Mandatory Reporting of adverse events including MIS, hospitalization/ fatal COVID	Mandatory Reporting of adverse events including MIS, hospitalization/ fatal COVID
Safety Patient self-reporting	Vsafe	Vsafe	Vsafe	Vsafe
Adverse events				
Solicited adverse reactions within 7 days after each dose.	Lasted 2-3 days, more adverse reactions after second dose Dose (%) 1 2 Pain at site 83.1. 78.0 Fatigue 47.4 59.4 Headache 41.9 51.7 Myalgia 21.3 37.3 Chills 14.0 35.1 Arthralgia 11.0. 21.9	Lasted 2-3 days, more adverse reactions after second dose Dose(%) 1 2 Pain at site 86.9 89.9 Fatigue. 38. 67.6 Headache 24.5. 19.3 Myalgia. 23.7 61.6 Chills 9.2 8.6 Arthralgia 16.6 45.5	(%) Pain 48.6 Erythema 7.3 Swelling 5.3 Headache 38.9 Fatigue 38.2 Myalgia 33.2 Nausea 14.2 Fever 9.0	(%) Pain/tenderness 82.2 Fatigue/malaise 62.0 Muscle pain 54.1 Headache 52.9 Joint pain 25.4 Nausea/vomiting 15.6 Injection site: Redness 7.0 Swelling 6.3 Fever 6.0

ACAAI COVID-19 VACCINE COMPARISON CHART – 08/24/2022

Vaccine	Pfizer-BioNTech	Moderna	J& J Vaccine	Novavax
Unsolicited	a) 12 cases of appendicitis reported b) Anaphylaxis -reported after EUA with first dose c) Myocarditis and pericarditis particularly following second dose d) Syncope e) Immunocompromised persons may have diminished response	a) 3 cases of Bell's palsy reported 22,28, 32 days after vaccination – b) 2 cases Facial swelling in vaccine recipients with history of dermatological fillers in 1-2 days c) 1 case of nausea, vomiting 1 day after vaccination d) Allergic reaction being investigated after EUA with first dose e) Large local vaccine site reaction onset after day 7/8 f) Myocarditis and pericarditis particularly following second dose g) Immunocompromised persons may have diminished response	a) Embolic and thrombotic events- 0.06% of vaccine recipients b) Tinnitus was reported in 6 vaccine recipients c) Angioedema 0.2% of vaccine recipients d) Urticaria e) arthritis (0.5%) f)) Peripheral neuropathy (0.2%) e) Guillain Barre Syndrome f) Thrombosis with thrombocytopenia syndrome (TTS) are rare side effects	a) Myocarditis - 2 cases b) Syncope c) Cardiomyopathy or cardiac failure - 8 cases d) Cholecystitis - 6 cases e) Non-cardiac, non-neurovascular thrombotic and embolic events - 11 cases f) Uveitis - 3 cases
Ingredients	1. Lipids - 0.43 mg (4-hydroxybutyl) azanediyl), bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg 2[(polyethylene glycol)-2000], N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-	1. Lipids- 1.93 mg (SM-102, polyethylene glycol [PEG] 2000,dimyristoyl glycerol [DMG], cholesterol,1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]) 2. 0.31 mg tromethamine,	1.Polysorbate 80 2. Citric acid mono hydrate 3.Trisodium citrate dihydrate 4.Hydroxypropyl Sodium chloride	1.The Matrix-M adjuvant is composed of Fraction-A (42.5 mcg) and Fraction-C (7.5 mcg) of saponin extracts from the soapbark tree, Quillaja saponaria Molina.

ACAAI COVID-19 VACCINE COMPARISON CHART – 08/24/2022

Vaccine	Pfizer-BioNTech	Moderna	J& J Vaccine	Novavax
	sn-glycero-3-phosphocholine, 0.2 mg cholesterol) 2. 0.01 mg potassium chloride 3. 0.01 mg monobasic potassium phosphate 4. 0.36 mg sodium chloride 5. 0.07 mg dibasic sodium phosphate dihydrate, 6. 6 mg sucrose	3. 1.18 mg tromethamine hydrochloride, 4. .043 mg acetic acid, 0.12 mg sodium acetate 5. 43.5 mg sucrose.	5. Sodium hydroxide 6. Hydrochloric acid	2. Cholesterol 3. Phosphatidylcholine 4. Potassium dihydrogen phosphate (3.85 mcg) 5.Potassium chloride (2.25 mcg) 6. Disodium hydrogen phosphate dihydrate (14.7 mcg) 7. Disodium hydrogen phosphate heptahydrate (2.465 mg) 8. Sodium dihydrogen phosphate monohydrate (0.445 mg) 9. Sodium chloride (8.766 mg) 10.Polysorbate 80 (0.050 mg)

Note: The FDA has limited the J&J vaccine to individuals for whom other authorized COVID-19 vaccines are not accessible or clinically appropriate, and to those who elect to receive the J&J vaccine because they would not otherwise receive a COVID-19 vaccine.